StratifAI

Executive Summary

StratifAI is a German AI biomarker company pioneering precision oncology through its proprietary Polaris™ platform. By integrating histology, RNA sequencing, and patient outcome data, Polaris enables the discovery and validation of novel biomarkers for cancer diagnostics. The company's lead product, Polaris™ Breast, is a diagnostic tool designed to assess metastatic risk in early breast cancer directly from routine histology slides. This approach aims to reduce over-treatment by identifying low-risk patients who may safely avoid chemotherapy, addressing a critical unmet need in oncology. StratifAI's technology leverages advanced machine learning to extract predictive insights from standard pathology images, offering a scalable and cost-effective solution for personalized cancer management. Founded in 2018 and based in Munich, the company operates at the intersection of computational pathology and biomarker development, occupying a niche with significant commercial potential as AI-driven diagnostics gain regulatory acceptance. While still in early stages without disclosed funding or revenue, StratifAI's platform has the potential to transform risk stratification in breast cancer and beyond, pending clinical validation and market adoption.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation data publication for Polaris Breast70% success
• Q2 2027Strategic partnership with diagnostic or pharma company50% success
• Q1 2027CE marking or regulatory submission in Europe60% success